Retrospective Study
Copyright ©The Author(s) 2022.
World J Diabetes. Jul 15, 2022; 13(7): 532-542
Published online Jul 15, 2022. doi: 10.4239/wjd.v13.i7.532
Table 5 Comparison of vascular density in the deep capillary plexus between the two groups (mean ± SD, %)
Groups
Before treatment
1 mo after treatment
3 mo after treatment
Fovea
Compaq group (n = 48)18.58 ± 3.8018.23 ± 3.7517.86 ± 4.12
Ranibizumab group (n = 48)19.14 ± 4.0018.78 ± 4.2418.47 ± 3.96
t value-0.703-0.673-0.740
P value0.4840.5020.461
Parafovea
Compaq group (n = 48)40.92 ± 5.7340.51 ± 4.8540.38 ± 5.22
Ranibizumab group (n = 48)40.40 ± 5.5140.10 ± 5.2839.56 ± 4.87
t value0.4530.3960.796
P value0.6510.6930.428
Overall macular area
Compaq group (n = 48)39.64 ± 4.8539.40 ± 4.7738.78 ± 4.62
Ranibizumab group (n = 48)40.43 ± 5.1839.93 ± 5.0339.52 ± 4.85
t value-0.771-0.530-0.765
P value0.4420.5980.446